Michael J. Currens

4.7k citations

26 papers · 3.9k indexed · 1 hit paper · h-index 18

Co-authors: Michael R. Boyd Robert H. Shoemaker Dominic A. Scudiero Anne Monks Sean Tierney Kenneth D. Paull James B. McMahon Robert W. Buckheit
Topics: HIV Research and Treatment (15 papers)HIV/AIDS drug development and treatment (14 papers)Natural product bioactivities and synthesis (4 papers)
Cited by: Virology Toxicology Biotechnology
Journals: Journal of Virology Biochemical and Biophysical Research Communications Journal of Medicinal Chemistry
Partner nations: United States Norway Italy

In The Last Decade

Michael J. Currens

26 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

1988 2.1k citations Dominic A. Scudiero, Robert H. Shoemaker et al. PubMed profile →

Peers

Countries citing papers authored by Michael J. Currens

Since Specialization

Citations

This map shows the geographic impact of Michael J. Currens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Currens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Currens more than expected).

Fields of papers citing papers by Michael J. Currens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Currens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Currens. The network helps show where Michael J. Currens may publish in the future.

Co-authorship network of co-authors of Michael J. Currens

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Currens. A scholar is included among the top collaborators of Michael J. Currens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Currens. Michael J. Currens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα 2012 ·Bioorganic & Medicinal Chemistry ·(unknown),Thomas G. McCloud,Dominic A. Scudiero,Michael J. Currens,John H. Cardellina,Robert H. Shoemaker	3
2	RSK2 Binding Models Delineate Key Features for Activity. 2010 ·PubMed ·Rick Gussio,Michael J. Currens,Dominic A. Scudiero,Jeffrey A. Smith,Deborah A. Lannigan,Robert H. Shoemaker,(unknown),Tam Luong Nguyen	2
3	Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis 2005 ·Antiviral Research ·Dorjbal Dorjsuren,(unknown),(unknown),Xulin Chen,Weimin Zhu,(unknown),Michael J. Currens,Robert H. Shoemaker,Robert P. Ricciardi,Shizuko Sei	31
4	Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Entry Inhibitors That Target the gp120-Binding Domain of CD4 2005 ·Journal of Virology ·(unknown),Andrew G. Stephen,Joseph W. Adelsberger,(unknown),Weimin Zhu,Michael J. Currens,(unknown),Bruce Crise,Robert J. Gorelick,Alan Rein,Robert J. Fisher,Robert H. Shoemaker,Shizuko Sei	41
5	Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity 2002 ·Biochemical and Biophysical Research Communications ·Andrew G. Stephen,Karen M. Worthy,Eric M. Towler,Judy A. Mikovits,Shizuko Sei,Paula Roberts,(unknown),Rhone K. Akee,(unknown),Thomas G. McCloud,(unknown),Alan Rein,David G. Covell,Michael J. Currens,Robert H. Shoemaker,Robert J. Fisher	47
6	Application of High-Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery 2002 ·Current Topics in Medicinal Chemistry ·Robert Shoemaker,Dominic A. Scudiero,Giovanni Melillo,Michael J. Currens,Anne Monks,Alfred A. Rabow,David G. Covell,Edward A. Sausville	69
7	Analysis of the Interaction between the HIV-Inactivating Protein Cyanovirin-N and Soluble Forms of the Envelope Glycoproteins gp120 and gp41 2000 ·Molecular Pharmacology ·Barry R. O’Keefe,Shilpa R. Shenoy,Dong Xie,Wentao Zhang,(unknown),Michael J. Currens,Irwin Chaiken,Michael R. Boyd	64
8	Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development 1997 ·Antimicrobial Agents and Chemotherapy ·Michael R. Boyd,Kirk R. Gustafson,James B. McMahon,Robert H. Shoemaker,Barry R. O’Keefe,Toshiyuki Mori,Robert J. Gulakowski,Lin Wu,(unknown),Carolyn M. Laurençot,Michael J. Currens,John H. Cardellina,Robert W. Buckheit,Peter L. Nara,Lewis K. Pannell,Raymond C. Sowder,Louis E. Henderson	483
9	Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Michael J. Currens,Jennifer Mariner,James B. McMahon,Michael R. Boyd	40
10	Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Michael J. Currens,Robert J. Gulakowski,Jennifer Mariner,(unknown),R W Buckheit,Kirk R. Gustafson,James B. McMahon,Michael R. Boyd	50
11	Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·James B. McMahon,R W Buckheit,Robert J. Gulakowski,Michael J. Currens,David T. Vistica,Robert H. Shoemaker,Sherman F. Stinson,(unknown),John P. Bader,V. L. Narayanan,Robert Schultz,W G Brouwer,(unknown),Michael R. Boyd	11
12	Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups 1995 ·Antiviral Research ·R W Buckheit,Valerie Fliakas-Boltz,Walter J. Decker,J. Alan Roberson,(unknown),(unknown),Elizabeth White,James B. McMahon,Michael J. Currens,Michael R. Boyd	59
13	A Reinvestigation of Maprounea Triterpenes 1995 ·Journal of Natural Products ·John A. Beutler,Yoel Kashman,Mark Tischler,John H. Cardellina,(unknown),Michael J. Currens,Monroe E. Wall,Mansukh C. Wani,Michael R. Boyd	14
14	Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms 1995 ·Antimicrobial Agents and Chemotherapy ·James B. McMahon,Michael J. Currens,Robert J. Gulakowski,Robert W. Buckheit,Carol Lackman-Smith,Yali F. Hallock,Michael R. Boyd	84
15	Bioactive Prenylated Hydroquinones from the SpongeSarcotragussp 1994 ·Natural product letters ·Richard W. Fuller,Michael J. Currens,John H. Cardellina,Michael R. Boyd	1
16	HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum 1992 ·Journal of Medicinal Chemistry ·Yoel Kashman,Kirk R. Gustafson,Ray W. Fuller,John H. Cardellina,James B. McMahon,Michael J. Currens,Robert W. Buckheit,S H Hughes,Gordon M. Cragg,Michael R. Boyd	465
17	Ability of Anti-HIV Agents to Inhibit HIV Replication in Monocyte/Macrophages or U937 Monocytoid Cells Under Conditions of Enhancement by GM-CSF or Anti-HIV Antibody 1990 ·AIDS Research and Human Retroviruses ·Carlo Federico Perno,David A. Cooney,Michael J. Currens,G Rocchi,David G. Johns,Samuel Broder,Robert Yarchoan	22
18	Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2′,3′-dideoxyguanosine 1990 ·Biochemical and Biophysical Research Communications ·Gurpreet S. Ahluwalia,David A. Cooney,(unknown),Michael J. Currens,Harry Ford,David G. Johns,Hiroaki Mitsuya,Arnold Fridland	20
19	In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors 1990 ·Antimicrobial Agents and Chemotherapy ·Seiji Hayashi,Robert L. Fine,Ting‐Chao Chou,Michael J. Currens,S Broder,Hiroaki Mitsuya	39
20	Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.breakdown → 1988 ·PubMed ·Dominic A. Scudiero,Robert H. Shoemaker,Kenneth D. Paull,Anne Monks,Sean Tierney,(unknown),Michael J. Currens,(unknown),Michael R. Boyd	2099

About Michael J. Currens

Michael J. Currens is a scholar working on Virology, Infectious Diseases and Toxicology, having authored 26 papers that have together received 3.9k indexed citations. Recurring topics across this work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (14 papers) and Natural product bioactivities and synthesis (4 papers). The work is most often cited by research in Virology (641 citations), Toxicology (147 citations) and Biotechnology (364 citations). Michael J. Currens has collaborated with scholars based in United States, Norway and Italy. Frequent co-authors include Michael R. Boyd, Robert H. Shoemaker, Dominic A. Scudiero, Anne Monks, Sean Tierney, Kenneth D. Paull, James B. McMahon, Robert W. Buckheit, Kirk R. Gustafson and Robert J. Gulakowski. Their work appears in journals such as Journal of Virology, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact